Graft Versus Host Disease (GvHD) Treatment Market Analysis By Application, Types, Region and Business Growth Drivers by 2032

BySanket Badgujar
MicrosoftTeams-image-666a8bfb

“The global Graft Versus Host Disease (GvHD) Treatment Market is expected to secure US$ 5,655.37 Million in 2032 while expanding at a CAGR of 8.3%.

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors.

Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

It is tough to diagnose who might develop GvHD after a transplant. Mild form of GvHD is observed in few cases. While in certain cases GvHD may be fatal. GvHD do not occur when recipient receives their own cells through autologous transplant. Prior to a transplant, cells from possible donors are screened to realize how strictly they match the recipient. Chances of GvHD are reduced, or symptoms will be milder, when the match is close.

There are two forms of GvHD:

  • Acute graft versus host disease (aGvHD).
  • Chronic graft versus host disease (cGvHD).

Graft Versus Host Disease (GvHD) Treatment Market: Drivers and Restraints

Presently, graft versus host disease (GvHD) market is driven by increase in number of incidence and prevalence of cancer patients which are treated by chemotherapy treatment. Graft versus host disease (GvHD) global market is also fueled by increase in number of bone marrow transplants been carried around the globe to treat specific types of cancers.

Increase in allogeneic hematopoietic stem cell transplant will play key role in global market for graft versus host disease (GvHD). However, cost linked with recent clinical trials and authorizations would acts as a major restraint for graft versus host disease (GvHD) global market.

Graft versus Host Disease (GvHD) Treatment Market: Overview

The global market graft versus host disease (GvHD) treatment is expected to register a healthy CAGR during the forecast period. Innovative development of novel technologies, and increase in the number of cancer patients seeking for chemotherapy treatment is expected to drive the growth of graft versus host disease (GvHD) treatment market in the forecast period (2016-2026).

Graft versus Host Disease (GvHD) Treatment Market: Key Players

Some of the key participating global players in graft versus host disease (GvHD) treatment global market are Sanofi, Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc., Soligenix, Inc., Mesoblast Ltd and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

  • Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
  • mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
  • Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
  • Thalidomide Graft Versus Host Disease (GvHD) Treatment
  • Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

  • Acute Graft Versus Host Disease (a(GvHD))
  • Chronic Graft Versus Host Disease (c(GvHD))

Graft Versus Host Disease (GvHD) Treatment Market by Region:

  • North America Graft Versus Host Disease (GvHD) Treatment Market
  • Latin America Graft Versus Host Disease (GvHD) Treatment Market
  • Europe Graft Versus Host Disease (GvHD) Treatment Market
  • Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market
  • Middle East & Africa Graft Versus Host Disease (GvHD) Treatment Market

0

0